JAK2 and neoplasm: Lastly, the use of VSV-GP, a potent oncolytic virus pseudotyped with the lymphocytic choriomeningitis virus (LCMV) envelope glycoprotein, together with the Jak1 and Jak2 inhibitor Ruxolitinib, led to transient tumour remission in mice following IP administration [42].